Radiation Dose Management Market Valued at $442 million in 2025, Set to Grow at a 7.2% CAGR

Radiation dose management market was valued at $442 million in 2025 and is projected to reach $881.3 million by 2035, growing at a CAGR of 6.2% during the forecast Period (2026-2035). Recent FDA clearance for low-dose radiation therapy for non-oncological conditions signifies an expanded regulatory acceptance, enhancing the scope of radiation dose management solutions and driving market growth. For instance, in March 2026, the US FDA granted 510(k) clearance to Varian (Siemens Healthineers) for its TrueBeam radiotherapy systems to support low-dose radiation therapy (LDRT) in osteoarthritis treatment. This development highlights increasing regulatory support for optimized and controlled radiation dose usage beyond oncology, strengthening the importance of dose management technologies.

Browse the full report description of “Radiation Dose Management Market Size, Share & Trends Analysis by Component (Software, and Services), By Modality (Computed Tomography (CT), Fluoroscopy & Interventional Imaging, Radiography & Mammography, and Nuclear Medicine), by Application (Oncology, Cardiology, Orthopedic Applications, and Others) and By End-User (Hospitals, Diagnostic Centres / Imaging Centres, Ambulatory Care Settings, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/radiation-dose-management-market

FDA Advancements in AI-Driven and Patient-Specific Radiation Dose Optimization Solutions

• In March 2025, DOSIsoft obtained FDA 510(k) clearance for PLANET Onco Dose version 3.2, a patient-specific dosimetry software used in nuclear medicine and radiation oncology. The solution enhances dose calculation accuracy across multiple radionuclide therapies, supporting compliance and personalized treatment planning.
• In September 2025, MVision AI received FDA 510(k) clearance for its Dose+ platform, an AI-driven solution designed to predict and optimize radiation dose during treatment planning. This reflects the growing FDA emphasis on integrating AI into radiation dose monitoring and improving precision in clinical workflows.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Therapeutic Type
  • By Drug Form
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AbbVie Inc., Eli Lilly and Co., Johnson & Johnson, Novo Nordisk A/S, Pfizer Inc., among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Radiation Dose Management Market Report Segment

By Therapeutic Type

• Dermatology
• Obesity
• Sexual Dysfunction
• Insomnia
• Depression / Anti-depressants
• Smoking Cessation
• Women’s Health / Contraceptives
• Others

By Drug Form

• Tablets
• Gels
• Oral Syrups
• Parenteral (Injectables)
• Creams
• Chewing Gums
• Others

By End-User

• Hospital-based Distribution
• Retail Pharmacies / Drug Stores
• Online Pharmacies / E-commerce Platforms
• Clinics & Specialty Centers
• Others

Global Radiation Dose Management Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/radiation-dose-management-market